Answers are grounded in this paper and cite their sources.
Dermatologists should be aware of the variety of cutaneous adverse events that can arise from the use of immunotherapeutic agents for hematologic malignancies.• Some cutaneous reactions to immunotherapeutic medications, such as pityriasiform eruption and blaschkitis, generally are benign and may not necessitate halting an important therapy.
No takes yet. Share an insight, caveat, or question.
Alexander J. Jafari (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: